» Articles » PMID: 23566358

Adult and Juvenile Dermatomyositis: Are the Distinct Clinical Features Explained by Our Current Understanding of Serological Subgroups and Pathogenic Mechanisms?

Overview
Publisher Biomed Central
Specialty Rheumatology
Date 2013 Apr 10
PMID 23566358
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Adult and juvenile dermatomyositis share the hallmark features of pathognomic skin rash and muscle inflammation, but are heterogeneous disorders with a range of additional disease features and complications. The frequency of important clinical features such as calcinosis, interstitial lung disease and malignancy varies markedly between adult and juvenile disease. These differences may reflect different disease triggers between children and adults, but whilst various viral and other environmental triggers have been implicated, results are so far conflicting. Myositis-specific autoantibodies can be detected in both adults and children with idiopathic inflammatory myopathies. They are associated with specific disease phenotypes and complications, and divide patients into clinically homogenous subgroups. Interestingly, whilst the same autoantibodies are found in both adults and children, the disease features remain different within autoantibody subgroups, particularly with regard to life-threatening disease associations, such as malignancy and rapidly progressive interstitial lung disease. Our understanding of the mechanisms that underlie these differences is limited by a lack of studies directly comparing adults and children. Dermatomyositis is an autoimmune disease, which is believed to develop as a result of an environmental trigger in a genetically predisposed individual. Age-specific host immune responses and muscle physiology may be additional complicating factors that have significant impact on disease presentation. Further study into this area may produce new insights into disease pathogenesis.

Citing Articles

Neutrophil and mononuclear leukocyte pathways and upstream regulators revealed by serum proteomics of adult and juvenile dermatomyositis.

Sparling A, Ward J, Sarkar K, Schiffenbauer A, Noroozi Farhadi P, Smith M Arthritis Res Ther. 2024; 26(1):196.

PMID: 39529136 PMC: 11552237. DOI: 10.1186/s13075-024-03421-7.


Contribution of major histocompatibility complex class II immunostaining in distinguishing idiopathic inflammatory myopathy subgroups: A histopathological cohort study.

Lessard L, Robert M, Fenouil T, Mounier R, Landel V, Carlesimo M J Neuropathol Exp Neurol. 2024; 83(12):1060-1075.

PMID: 39283714 PMC: 11576552. DOI: 10.1093/jnen/nlae098.


Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index.

Rosina S, Consolaro A, Pistorio A, Rebollo-Gimenez A, Bracaglia C, Dolezalova P RMD Open. 2024; 10(1).

PMID: 38307698 PMC: 10840041. DOI: 10.1136/rmdopen-2023-003093.


Development of a computed tomography calcium scoring technique for assessing calcinosis distribution, pattern and burden in dermatomyositis.

Cervantes B, Gowda P, Rider L, Miller F, Chen M, Schiffenbauer A Rheumatology (Oxford). 2023; 63(1):58-63.

PMID: 37286372 PMC: 10765154. DOI: 10.1093/rheumatology/kead256.


Calcinosis in juvenile dermatomyositis: Updates on pathogenesis and treatment.

Pinotti C, Cannon L, Dvergsten J, Wu E Front Med (Lausanne). 2023; 10:1155839.

PMID: 36936211 PMC: 10017873. DOI: 10.3389/fmed.2023.1155839.


References
1.
Callen J . Relation between dermatomyositis and polymyositis and cancer. Lancet. 2001; 357(9250):85-6. DOI: 10.1016/S0140-6736(00)03535-2. View

2.
Trapani S, Camiciottoli G, Vierucci A, Pistolesi M, Falcini F . Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study. Rheumatology (Oxford). 2001; 40(2):216-20. DOI: 10.1093/rheumatology/40.2.216. View

3.
McCann L, Li C, Varsani H, Wedderburn L, Pilkington C . Failure to over express MHC-CLASS-1 on muscle biopsy in a case of amyopathic juvenile dermatomyositis. Clin Exp Rheumatol. 2007; 25(1):96-8. View

4.
McCann L, Juggins A, Maillard S, Wedderburn L, Davidson J, Murray K . The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006; 45(10):1255-60. DOI: 10.1093/rheumatology/kel099. View

5.
TOPI G, DAlessandro L, Catricala C, ZARDI O . Dermatomyositis-like syndrome due to toxoplasma. Br J Dermatol. 1979; 101(5):589-91. View